# A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

> **NCT05485974** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **HUYABIO International, LLC.** · enrollment: 44 (estimated)

## Conditions studied

- Lung Cancer
- Non Small Cell Lung Cancer
- Colorectal Cancer
- Cancer of Pancreas
- Colon Cancer
- Solid Tumor
- Cancer

## Interventions

- **DRUG:** HBI-2438

## Key facts

- **NCT ID:** NCT05485974
- **Lead sponsor:** HUYABIO International, LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05485974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05485974, "A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05485974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*